TARPON SPRINGS, Fla., April 25, 2025 -- Allarity Therapeutics, Inc. (“Allarity” or the “Company”) (NASDAQ: ALLR), a Phase 2 clinical-stage pharmaceutical company dedicated to developing stenoparib—a differentiated, dual PARP and WNT pathway inhibitor—as a personalized cancer treatment using its proprietary, drug-specific Drug Response Predictor (DRP®) patient selection technology today announced the presentation of a poster containing data on a new DRP for the monoclonal antibody drug daratumumab. The post ...

Exhibit 99.1 Allarity Therapeutics Reports Full Year 2024 Financial Results and Provides a Business Update - Cash and cash receivable balance of $20.9 million as of December 31, 2024, expected to fund operations, including clinical activities into 2027 - Strengthened cash position expected to support the Company through first substantive data readout in its Phase 2 ovarian cancer trial, with enrollment scheduled to begin H1 2025 - Enrollment in new Phase 2 SCLC trial to begin in Q2-Q3 2025, fully funded by ...

Boston (March 31, 2025)—Allarity Therapeutics, Inc. ("Allarity" or the "Company") (NASDAQ: ALLR), a Phase 2 clinical-stage pharmaceutical company dedicated to developing stenoparib—a differentiated, dual PARP/WNT pathway inhibitor—today announced financial results for the year ended December 31, 2024, and provided a general business update. Thomas Jensen, Chief Executive Officer of Allarity Therapeutics, stated: "2024 was a transformational year for Allarity as we made significant progress in advancing sten ...

Core Viewpoint - Allarity Therapeutics has engaged Shareholder Intelligence Services to investigate potential illegal naked short selling and trading irregularities in its stock, emphasizing its commitment to protecting shareholder value and ensuring fair trading practices [1][2][3]. Group 1: Engagement with ShareIntel - The collaboration with ShareIntel aims to monitor trading activities and detect unusual short-selling patterns, utilizing ShareIntel's DRIL-Down™ technology for compliance-driven data analytics [2][3]. - Allarity will take corrective actions, including legal recourse if necessary, based on the findings from ShareIntel's investigation [2][3]. Group 2: CEO's Statement - The CEO of Allarity highlighted the importance of this engagement in fostering market confidence and addressing notable stock volatility observed by the company [3]. - The company aims to ensure that its shares are traded fairly and free from manipulation as it advances the clinical development of stenoparib [3]. Group 3: About Stenoparib - Stenoparib is a dual-targeted inhibitor of PARP1/2 and tankyrase 1/2, showing potential as a therapeutic for various cancers, particularly ovarian cancer [4]. - The drug's unique mechanism involves inhibiting PARP and blocking Wnt pathway activation, which is significant in cancer progression [4]. Group 4: Company Overview - Allarity Therapeutics is focused on developing personalized cancer treatments and has secured exclusive global rights for the development and commercialization of stenoparib [5]. - The company utilizes its DRP technology to create companion diagnostics aimed at selecting patients who would benefit most from stenoparib [5].

Core Viewpoint - The Schall Law Firm is investigating Allarity Therapeutics, Inc. for potential violations of securities laws related to misleading statements and undisclosed information [1][2]. Group 1: Investigation Details - The investigation centers on whether Allarity issued false or misleading statements and failed to disclose relevant information to investors [2]. - Allarity filed a Form 8-K with the SEC on July 22, 2024, indicating that it received a "Wells Notice" from the SEC regarding its disclosures related to meetings with the FDA concerning its New Drug Application for Dovitinib [2]. - The Wells Notice also indicated that three former officers of Allarity received similar notices from the SEC, and the SEC staff has made a preliminary determination to recommend enforcement action against the Company for alleged violations of federal securities laws [2].

     The Annual Meeting is the foremost educational and scientific event for gynecologic oncologistsStenoparib has shown clinical benefit in heavily pre-treated patients, including those with platinum-resistant and refractory ovarian cancerFindings may reflect stenoparib's dual PARP/Wnt pathway inhibition Boston (March 17, 2025)—Allarity Therapeutics, Inc. ("Allarity" or the "Company") (NASDAQ:ALLR), a Phase 2 clinical-stage pharmaceutical company dedicated to developing stenoparib—a differentiated dual PA ...

Core Viewpoint - The Schall Law Firm is investigating Allarity Therapeutics, Inc. for potential violations of securities laws related to misleading statements and undisclosed information [1][2]. Group 1: Investigation Details - The investigation centers on whether Allarity issued false or misleading statements and failed to disclose relevant information to investors [2]. - Allarity filed a Form 8-K with the SEC on July 22, 2024, indicating that it received a "Wells Notice" from the SEC regarding its disclosures related to meetings with the FDA concerning its New Drug Application for Dovitinib [2]. - The Wells Notice also indicated that three former officers of Allarity received similar notices from the SEC, suggesting a broader issue within the company's management [2]. Group 2: SEC Actions - The Wells Notice informed Allarity that the SEC staff has made a preliminary determination to recommend an enforcement action against the company for alleged violations of federal securities laws [2].

Core Viewpoint - Allarity Therapeutics has reached a final settlement with the U.S. SEC regarding past disclosures related to its New Drug Application for Dovitinib, resolving all regulatory and legal challenges [1][2][3] Settlement Details - The settlement includes a one-time civil penalty of $2.5 million, with Allarity consenting to an administrative cease-and-desist order without admitting or denying the SEC's findings [2][4] - The SEC's investigation found violations of non-scienter-based provisions under Sections 17(a)(2) and (3) of the Securities Act of 1933, as well as Section 13(a) of the Securities Exchange Act of 1934 [2] Company Focus - With the resolution of legal matters, Allarity can now concentrate on advancing its clinical development plans for stenoparib, a dual PARP/Wnt pathway inhibitor [4] - The company has indicated that its cash position is expected to support operations into 2026, and the civil penalty will not affect its financial outlook or clinical programs [4] Product Information - Stenoparib is an orally available, small-molecule dual-targeted inhibitor of PARP1/2 and tankyrase 1/2, showing potential for treating various cancers, including advanced ovarian cancer [5] - Allarity holds exclusive global rights for the development and commercialization of stenoparib, which was originally developed by Eisai Co. Ltd. [5] Company Overview - Allarity Therapeutics is a clinical-stage biopharmaceutical company focused on developing personalized cancer treatments, particularly through its DRP® technology for companion diagnostics [6]

Core Viewpoint - Allarity Therapeutics is advancing a Phase 2 trial for stenoparib in combination with temozolomide to treat recurrent Small Cell Lung Cancer (SCLC), fully funded by the U.S. Veterans Administration, aiming to address significant unmet medical needs in this patient population [1][7][10]. Company Overview - Allarity Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing personalized cancer treatments, particularly stenoparib, a dual PARP/tankyrase inhibitor [13]. - The company is headquartered in the U.S. and has a research facility in Denmark, committed to addressing significant unmet medical needs in cancer treatment [13]. Clinical Study Design - The Phase 2 trial will enroll approximately 65 extensive-stage SCLC patients across 11 VA medical centers, assessing progression-free survival and determining the recommended Phase 2 dose during an initial safety lead-in phase [5]. Mechanism of Action - Stenoparib is a dual PARP and tankyrase inhibitor that enhances the efficacy of temozolomide by blocking DNA repair mechanisms, potentially increasing cancer cell death and addressing treatment resistance associated with SCLC [2][6][8]. - The combination aims to overcome resistance mechanisms such as the MGMT enzyme and mismatch repair deficiencies that limit the effectiveness of temozolomide [8]. Funding and Financial Considerations - The trial is fully funded by the U.S. Veterans Administration, ensuring that it will not impact Allarity's financial outlook or other clinical programs [10]. - Allarity's cash position is reported to support operations into 2026, indicating a stable financial foundation for ongoing and future projects [10]. Regulatory Status - Investigators are in the process of obtaining final regulatory approvals from the U.S. Food and Drug Administration, the VA, and the Institutional Review Board before patient enrollment can begin [9].

Core Viewpoint - Allarity Therapeutics has authorized a share repurchase program of up to $5 million, reflecting the company's confidence in its future and commitment to delivering value to shareholders and patients [1][2][3] Group 1: Share Repurchase Program - The share repurchase program allows Allarity to buy back up to $5 million of its common stock through February 28, 2026, without affecting its financial runway [1][2] - The program is discretionary, meaning the company can repurchase shares at its own pace and under market conditions, complying with legal requirements [3][4] Group 2: Company Confidence and Future Plans - The CEO of Allarity expressed confidence in the long-term vision and clinical potential of stenoparib, particularly for treating advanced ovarian cancer [3] - The company plans to initiate patient enrollment soon under a new trial protocol to further investigate stenoparib's dual mechanisms of action [3] Group 3: About Stenoparib - Stenoparib is a dual-targeted inhibitor of PARP1/2 and tankyrase 1/2, showing promise in treating various cancers, especially ovarian cancer [5] - The drug has exclusive global rights for development and commercialization, originally developed by Eisai Co. Ltd. [5] Group 4: Drug Response Predictor (DRP) - Allarity utilizes its proprietary Drug Response Predictor (DRP) to identify patients likely to benefit from stenoparib based on gene expression signatures [6] - The DRP platform has demonstrated the ability to predict clinical outcomes from drug treatment in numerous studies, enhancing the therapeutic benefit rate [6]